These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 36118132)
41. Molecular Characteristics and the Effect of Gu G; Yu B; Wan H; Lu S; Zhu X; Zhao Y; Fuxi Y; Liu C Onco Targets Ther; 2022; 15():1021-1032. PubMed ID: 36172169 [TBL] [Abstract][Full Text] [Related]
42. The Prevalence and Concurrent Pathogenic Mutations of Liu Y; Li H; Zhu J; Zhang Y; Liu X; Li R; Zhang Q; Cheng Y Cancer Manag Res; 2021; 13():2447-2454. PubMed ID: 33758543 [TBL] [Abstract][Full Text] [Related]
52. Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma. Calles A; Sholl LM; Rodig SJ; Pelton AK; Hornick JL; Butaney M; Lydon C; Dahlberg SE; Oxnard GR; Jackman DM; Jänne PA Clin Cancer Res; 2015 Jun; 21(12):2851-60. PubMed ID: 25737507 [TBL] [Abstract][Full Text] [Related]
53. The Activity of Immune Checkpoint Inhibition in KRAS Mutated Non-small Cell Lung Cancer: A Single Centre Experience. Torralvo J; Friedlaender A; Achard V; Addeo A Cancer Genomics Proteomics; 2019; 16(6):577-582. PubMed ID: 31659111 [TBL] [Abstract][Full Text] [Related]
54. Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets. Rekhtman N; Pietanza MC; Hellmann MD; Naidoo J; Arora A; Won H; Halpenny DF; Wang H; Tian SK; Litvak AM; Paik PK; Drilon AE; Socci N; Poirier JT; Shen R; Berger MF; Moreira AL; Travis WD; Rudin CM; Ladanyi M Clin Cancer Res; 2016 Jul; 22(14):3618-29. PubMed ID: 26960398 [TBL] [Abstract][Full Text] [Related]
55. Loss of p53 attenuates the contribution of IL-6 deletion on suppressed tumor progression and extended survival in Kras-driven murine lung cancer. Tan X; Carretero J; Chen Z; Zhang J; Wang Y; Chen J; Li X; Ye H; Tang C; Cheng X; Hou N; Yang X; Wong KK PLoS One; 2013; 8(11):e80885. PubMed ID: 24260500 [TBL] [Abstract][Full Text] [Related]
56. Clinicopathologic characteristics and survival outcome in patients with advanced lung adenocarcinoma and Yang S; Yu X; Fan Y; Shi X; Jin Y J Cancer; 2018; 9(16):2930-2937. PubMed ID: 30123361 [TBL] [Abstract][Full Text] [Related]
57. The prognostic impact of KRAS, its codon and amino acid specific mutations, on survival in resected stage I lung adenocarcinoma. Izar B; Zhou H; Heist RS; Azzoli CG; Muzikansky A; Scribner EE; Bernardo LA; Dias-Santagata D; Iafrate AJ; Lanuti M J Thorac Oncol; 2014 Sep; 9(9):1363-9. PubMed ID: 25122432 [TBL] [Abstract][Full Text] [Related]
58. Clinicopathologic characteristics of EGFR, KRAS, and ALK alterations in 6,595 lung cancers. Lee B; Lee T; Lee SH; Choi YL; Han J Oncotarget; 2016 Apr; 7(17):23874-84. PubMed ID: 26992209 [TBL] [Abstract][Full Text] [Related]
59. Outcomes of patients with stage III non-small cell lung cancer (NSCLC) that harbor a An J; Yan M; Yu N; Chennamadhavuni A; Furqan M; Mott SL; Loeffler BT; Kruser T; Sita TL; Feldman L; Nguyen R; Pasquinelli M; Hanna NH; Abu Hejleh T Transl Lung Cancer Res; 2021 Aug; 10(8):3608-3615. PubMed ID: 34584860 [TBL] [Abstract][Full Text] [Related]
60. KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden. Marinelli D; Mazzotta M; Scalera S; Terrenato I; Sperati F; D'Ambrosio L; Pallocca M; Corleone G; Krasniqi E; Pizzuti L; Barba M; Carpano S; Vici P; Filetti M; Giusti R; Vecchione A; Occhipinti M; Gelibter A; Botticelli A; De Nicola F; Ciuffreda L; Goeman F; Gallo E; Visca P; Pescarmona E; Fanciulli M; De Maria R; Marchetti P; Ciliberto G; Maugeri-Saccà M Ann Oncol; 2020 Dec; 31(12):1746-1754. PubMed ID: 32866624 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]